Cite
HARVARD Citation
Saad, E. et al. (2019). Disease-free survival as a surrogate for overall survival in patients with HER2-positive, early breast cancer in trials of adjuvant trastuzumab for up to 1 year: a systematic review and meta-analysis. Lancet oncology. 20 (3), pp. 361-370. [Online].